logo
Nonprofit offers free dental work to some low-income, uninsured Oklahomans

Nonprofit offers free dental work to some low-income, uninsured Oklahomans

Yahoo24-03-2025

OKLAHOMA CITY (KFOR) – A nonprofit is working to connect hundreds of low-income and uninsured Oklahomans to dentists for free dental work. It's changing lives, one tooth at a time.
One patient told News 4, after years of only eating soft foods, he can finally sink his teeth into his favorite dishes.
LOCAL NEWS: Starting fires to prevent fires, preparing for another round of wildfires
'Fried chicken,' said Tyron Barnes.
A trip to the dentist's office isn't always at the top of everyone's list, but it's necessary.
That was the case for Barnes. He said his medication caused his teeth to decay over time. He said he only had eight teeth for 12 years.
'I was missing all my uppers,' said Barnes.
However, Barnes didn't have insurance. To fix his smile would've been thousands of dollars.
Thankfully, he found D-Dent.
D-Dent is a nonprofit that provides expensive dental care to veterans, the elderly, the disabled, and people with life-threatening illnesses like cancer.
The best part is…
'100% free. No cost to the people we help,' said Karen Chadwell, the executive director of D-Dent.
Chadwell is at the root of D-Dent. During the program's nearly 40 years, it's been responsible for more than 20,000 smiles and free treatments totaling more than $29 million.
Dr. Adam Brewer has helped hundreds of patients, with D-Dent, for about 15 years.
'Giving ten people dentures on the same day, that's fun,' said Dr. Brewer. 'It's ten smiles like Tyron.'
Clients can call D-Dent or fill out an application online. To qualify, you must be low-income and uninsured. Then, they'll connect you with a dentist in your area.
LOCAL NEWS: Tips on protection against wildfires & potential evacuations
'We try to get you as close as we can to where you live,' said Chadwell. 'They do the work for free and then d-dent pays for any lab bills.'
D-Dent does not cover implants.
They'll walk you through appointments and questions.
Barnes said the process was as smooth as a freshly polished tooth. Best of all, it was painless.
'Don't discount yourself. At least try,' said Barnes.
'When you don't have teeth, it's very noticeable,' said Dr. Brewer. 'When you get them back, then it's like the world sees you again.'
The non-profit lives off of grants and donations. They're fundraiser 'BBQ, Boots & Brews' is coming up on April 12th.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Benefits resource fair, claims clinic set for Ramsey County vets
Benefits resource fair, claims clinic set for Ramsey County vets

Yahoo

time3 hours ago

  • Yahoo

Benefits resource fair, claims clinic set for Ramsey County vets

Local veterans can learn more about benefits and healthcare options at a Veterans Resource Fair and Claims Clinic on Thursday. The event, held by the Department of Veteran Affairs and the Ramsey County Veterans Service Offices, will be held from 11 a.m. to 3 p.m. Thursday, June 12, at the Rondo Community Library, 461 Dale St. N., St. Paul. Veterans can speak to representatives from the Minneapolis VA Medical Center, St. Paul Veterans Benefits Administration Regional Office and the Ramsey County Veterans Service. In addition, veterans can work with Veterans Affairs claim processors on disability compensation claims and benefit questions. Walk-ins are welcome but appointments can also be made online at Veterans are asked to bring a copy of their DD214 and any recent VA claim correspondence they may have. Officials say there are nearly 20,000 veterans in Ramsey County. Officials say that 11,000 of them are not using benefits or healthcare they are entitled to have. D-Day veterans return to Normandy to mark 81st anniversary of landings The man whose weather forecast saved the world WWII vets are rock stars in France as they hand over the duty of remembering D-Day Minnesota veterans with PTSD turn to the outdoors to improve mental health Minnesota political leaders emphasize support for veterans at Fort Snelling program

King Charles Offers Rare Health Comment Amid Reports His Cancer Is ‘Incurable' After ‘Refusing' Chemotherapy
King Charles Offers Rare Health Comment Amid Reports His Cancer Is ‘Incurable' After ‘Refusing' Chemotherapy

Yahoo

time5 hours ago

  • Yahoo

King Charles Offers Rare Health Comment Amid Reports His Cancer Is ‘Incurable' After ‘Refusing' Chemotherapy

King Charles is making light of the topic of health amid his own internal crisis. The King just quipped with a veteran about his old age, and dropped a secret to living a long life. In an event for a ceremony of keys outside Lancaster castle, Richard Brock had the opportunity to briefly talk to the Monarch. The 101-year-old D-Day veteran received some sage advice from Charles after saying that he looked 'fantastic' at his age. The King said, 'Keep drinking the whisky.' More from StyleCaster King Charles' Cancer Reportedly Incurable As Reports Claim He 'May Die' After He 'Refused Chemotherapy' Princess Alexandra Subtly Took a Side in Charles & Harry's Feud Amid Reports There's 'No Turning Back' in Their Relationship 'He (the King) just told me I was amazing for my age,' Brock said of the conversation. His son Tony Brock also recalled the moment, 'He mentioned a nip of whisky and said to keep taking it.'The unexpected health advice comes right after royal insider Camilla Tominey reported that King Charles' cancer is incurable. 'The talk now is that he may die 'with' cancer, but not 'of' cancer following a rigorous treatment program,' she revealed in The Telegraph. She also confirmed that King Charles' 80th anniversary plans in 2028 are 'tentative' due to his ailing health. Other sources were scared for the future of King Charles because of how he has been responding to treatments. 'Charles is indeed a sick man, and he does have cancer,' an insider told NewsNationNow. 'He also refused chemotherapy and decided on a less invasive treatment.' It's the complete opposite of what a royal aide said King Charles's health. He is dealing 'incredibly well' with cancer, the anonymous insider told The Telegraph. 'The thing you learn about this illness is that you just manage it and that's what he does. Medical science has made incredible advances and I genuinely see no difference in him. As long as you just do what the doctors say, just live your life as normal as possible… that's exactly what he is doing.' Charles' mortality has been put in the spotlight after Prince Harry dropped his bombshell interview where he pleaded for reconciliaton with his family. 'Life is precious. I don't know how much longer my father has,' the Duke of Sussex said in an interview with the BBC. 'He won't speak to me because of this security stuff, but it would be nice to reconcile.' Best of StyleCaster The 26 Best Romantic Comedies to Watch if You Want to Know What Love Feels Like These 'Bachelor' Secrets & Rules Prove What Happens Behind the Scenes Is So Much Juicier BTS's 7 Members Were Discovered in the Most Unconventional Ways

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

Yahoo

timea day ago

  • Yahoo

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store